COVID
Appearance
Risk factors for severe disease
- Epidemiological
- Age >65
- Hx chronic lung disease
- Hx CVD
- Diabetes, CKD, CLD
- Transplant/cancer/immunosppuression
- NH or long-term care facility
- BMI > 40
- Clinical
- RR > 244
- HR > 125
- Sats < 94% RA
- Labs
- Elevated D-dimer, CK, LDH, ferriting, troponin, CRP > 100, low lymphocytes
Admission:
- Mild/moderate COVID patients with no no risk factors for deterioration could be considered for home management
- Supportive care
- Daily telehealth, back to fever clinic if worse
- COVID-CARE monitoring
- Severity
- Asymptomatic
- Mild - no SOB/dyspnoea/abnormal chest imaging
- Mod - evidence of LRT involvement and O2 sat >94% on RA
- Severe - any of
- Sats<94% RA
- RR > 30
- Lung infiltrates >50%
- Pa02/Fi02 < 300mmHg
- Critical
- Respiratory failure
- Septic shock
- MODS
- Bloods
- FBE, UEC, LFT
- Ferritin, CRP, D-dimer
- aPTT/PT, fibrinogen
- LDH
- CK/Trop
- bHCG?
- Imaging
- CXR
- CT if empyema/lung abscess suspected
- Medications
- Continue statins, anticoagulants, antiplatelets, ACE/ARB
- Prefer MDI via spacer
- Clexane for hospitalised nonpregnant adults - prophylactic
Handover
- Symptoms
- Severity
- Epidemiological exposure
- Vaccines and dates
- Date of first positive swab
- Day of illness
- RFs
- Clinical parameters
- Bloods indicating severe disease
- GOC
Inpatient:
- Bloods
- Mod/severe - 3x weekly
- Escalating O2 requirement
- Awake proning if
- GCS 15
- BMI < 30 and <95kg total body weight
- Independently mobile
- Patient happy to do it
- Sats <92% on 4L via NP
- Consultant should be aware
- Do it for 12-16 hours
- Avoid IVF if possible
Management
- Mild
- Sotrovimab unless fully vaccinated, also if immunosuppressed regardless vaccination status
- Must be <5 days since onset
- Must have no O2 requirement
- Must have one of
- Diabetes requiring meds
- BMI > 30
- CKD eGFR<60
- CCF NYHA class II or greater
- Asthma requiring some sort of steroids in past year
- Age > 55
- COPD
- No steroids
- Sotrovimab unless fully vaccinated, also if immunosuppressed regardless vaccination status
- Moderate
- Supportive care
- Consider clinical trials
- Severe
- Dexamethasone or dexamethasone + remdesivir
- Only in patients with Sp02 < 92% RA
- Remdesivir should ideally be used within 7 days of onset
- Tocilizumab or baricitinib
- If deteriorating within 3/7 of admission AND CRP > 75
- Requires high-flow device or NIV
- Approval required from on-call COVID-ID consultant - may need clinical trial
- Monitor serum procalcitonin prior to tocilizumab, daily after the dose and prior to any subsequent dose
- Prophylactic ivermectin may be required - discuss with ID - depends whether patient comes from area endemic with strongyloides?
- Dexamethasone or dexamethasone + remdesivir
- Critical
- Dexamethasone
- +/- tocilizumab
- Can't tell what the guideline is saying - I think if patient goes to ICU on ECMO or mechanical ventilation they need tocilizumab as well